TYK Medicines, Inc. Class H stock analysis
Want to see HK:2410 full AI Analyst Report?
TYK Medicines, Inc. Class H (2410) Stock Price & Analysis
2410 Stock Chart & Stats
- Day’s Range
- HKD 3.57 - HKD 3.99
- 52-Week Range
- HKD 2.41 - HKD 14.95
- Previous Close
- HKD 3.86
- Volume
- N/A
- Average Volume (3M)
- 490.15K
- Market Cap
- HKD 1.47B
- Enterprise Value
- HKD 2.11B
- Total Cash (Recent Filing)
- HKD 201.96M
- Total Debt (Recent Filing)
- HKD 149.63M
- Price to Earnings (P/E)
- ―
- Beta
- 1.80
- Next Earnings
- Apr 01, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Targeted Oncology Pipeline
A focused small-molecule oncology strategy can support specialized expertise, differentiated candidate selection, and a coherent research platform. Advancing targeted therapies through multiple development stages creates the potential for pipeline value and future commercial opportunities if clinical execution succeeds.
Manageable Current Leverage
Recent leverage appears manageable, which reduces the immediate burden of debt service and preserves more flexibility for research investment. This provides a relatively stable financing base compared with an over-geared biotech, although it does not eliminate the need for future funding.
Improving Loss Trend
The smaller TTM loss suggests that reported performance has improved from earlier periods, potentially reflecting cost control or other improvements. If sustained, narrower losses could extend the company’s operating runway and reduce the pace at which it must seek additional capital.
Bears Say
Minimal Recurring Revenue
The absence of meaningful recurring revenue leaves the business dependent on research progress rather than an established commercial base. This limits operating leverage and revenue visibility, making near-term financial performance highly sensitive to development outcomes and future commercialization.
Persistent Operating Losses
Large ongoing losses indicate that the current business model has not yet generated sustainable earnings power. Continued deficits can constrain investment flexibility, make results dependent on external capital, and increase the financial consequences of delays or setbacks in drug development.
Heavy Cash Burn And Funding Need
Substantial negative operating and free cash flow means the company consumes cash to sustain research and operations rather than funding them internally. Continued burn is likely to require external financing, creating dilution or financing risk and potentially limiting strategic flexibility.
TYK Medicines, Inc. Class H News
TYK Medicines Wins Conditional China Nod for Next‑Generation Lung Cancer Drug
TYK Medicines, Inc. Class H ( ($HK:2410) ) has provided an announcement. TYK Medicines, Inc. announced that its self‑developed Asandeutertinib Mesylate Tablets (TY‑9591), a next‑generation, irreversible and highly selective EGFR‑TKI,
2410 FAQ
What was TYK Medicines, Inc. Class H’s price range in the past 12 months?
What is TYK Medicines, Inc. Class H’s market cap?
When is TYK Medicines, Inc. Class H’s upcoming earnings report date?
How were TYK Medicines, Inc. Class H’s earnings last quarter?
Is TYK Medicines, Inc. Class H overvalued?
Does TYK Medicines, Inc. Class H pay dividends?
What is TYK Medicines, Inc. Class H’s EPS estimate?
How many shares outstanding does TYK Medicines, Inc. Class H have?
What happened to TYK Medicines, Inc. Class H’s price movement after its last earnings report?
Which hedge fund is a major shareholder of TYK Medicines, Inc. Class H?
What is the TipRanks Smart Score and how is it calculated?
TYK Medicines, Inc. Class H Stock Smart Score
Company Description
TYK Medicines, Inc. Class H
TYK Medicines, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, obtaining, advancing, and bringing to market innovative treatments for significant unmet needs in oncology. The company's primary drug candidate, TY-9591, is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It is being developed to treat non-small cell lung cancer (NSCLC) with EGFR mutations that has metastasized to the brain, as well as locally advanced or metastatic NSCLC characterized by the EGFR L858R mutation. Beyond its lead candidate, TYK Medicines maintains a diverse pipeline of other investigational therapies. These include TY-302, an oral cyclin-dependent kinase (CDK) 4/6 inhibitor designed for solid tumors such as breast and prostate cancer. Another compound, TY-2136b, is an oral ROS proto-oncogene 1/neurotrophic tyrosine receptor kinase inhibitor also aimed at solid tumors. The company is advancing TY-2699a, a selective CDK7 inhibitor, and TY-0540, a selective CDK2/4/6 inhibitor, both targeting advanced or metastatic solid malignancies. Further, the pipeline features TY-4028, an oral exon 20 insertion tyrosine kinase inhibitor (TKI) specifically addressing locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 or HER2 exon 20 insertions. TY-1091 is a potent and selective rearranged during transfection proto-oncogene (RET) inhibitor, under development for advanced NSCLC with RET gene fusion, advanced medullary thyroid cancer with RET gene mutation, and other solid tumors presenting RET gene alterations. Other promising programs include TY-1054, an oral yes-associated protein-transcriptional enhanced associate domain inhibitor for various cancers; TY-1210, a selective CDK2 inhibitor for solid tumors; TY-0609, a selective CDK4 inhibitor also for cancer therapy; and TY-3200, an innovative EGFR degrader. Established in 2017, the enterprise operates from its main office located in Huzhou, China.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Yusheng Wu
- Employees
- 184
- Website
- www.tykmedicines.com
- Address
- CN
TYK Medicines, Inc. Class H (2410) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 10 | 2 | 10 |
| Technical Analysis | 3 | 2 | 5 |
| Moving Averages | 7 | 0 | 5 |
